Myricetin attenuates the inflammatory bowel disease in prediabetic mice <i>via</i> inflammation inhibition and gut microbiota modulation

Abstract Myricetin shows great anti‐inflammatory effect on colitis and supplementation with myricetin could improve gut microbiota dysbiosis. It is reported that the abnormal blood glucose condition of prediabetes could aggravate the progression of inflammation. However, there is no report on whether myricetin has the protective effect on inflammation comorbid prediabetes. This study aimed to explore the effect and potential mechanism of myricetin on dextran sulfate sodium (DSS)‐induced colitis in prediabetic mice. Several indexes related to colitis were evaluated on DSS‐induced prediabetic mice. Myricetin intervention improved body weight loss, disease activity index score in DSS‐induced colitis in prediabetic mice. Myricetin alleviated inflammation by inhibiting proinflammatory cytokines and myeloperoxidase production in DSS‐induced colitis in prediabetic mice. Furthermore, myricetin showed recovery of intestinal barrier integrity by increasing the expression of tight junction proteins ( ZO‐1 , Occludin and Claudin‐1 ). At the gut microbiota level, myricetin showed protective effects via modulating gut dysbiosis associated with DSS‐induced colitis in prediabetic mice. In addition, myricetin could significantly increase the short chain fatty acids produced by gut microbiota. Myricetin may be serving as a novel therapeutic agent which could be used in the treatment of DSS‐induced colitis in prediabetic patients in the future with its added value as well reported antidiabetic agent.